Clinical evaluation company The IMA Group (IMA) revealed on Tuesday the completion of the acquisition of Diagnostics Research Group (DXRG) in San Antonio, Texas for an undisclosed amount.
Diagnostics Research Group (DXRG) reportedly provides expertise across a diverse array of medical specialties, including vaccine and medical device development, internal medicine, allergies and pulmonary and fatty liver diseases.
Following closing, DXRG will continue to operate under its current name, with key leadership, investigators and staff remaining in place.
The acquisition which marks IMA's fourth this year adds to its growing Clinical Research Division and aligns with its mission to reach people everywhere as it partners with its sponsors to develop safe and effective new treatments. In addition it extends its access to diverse patient populations and its expansion into the southwestern US.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma